Every 10-Q that VYCOR MEDICAL INC (VYCO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow VYCO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VYCO filings page.
Vycor Medical, Inc. reported lower revenue and a small net loss for the six months ended June 30, 2026 while continuing to face significant financial strain. Revenue was $876,804, down from $932,731 a year earlier, with Vycor Medical neurosurgical products generating $841,665 and NovaVision $35,139. Consolidated gross profit was $719,598, or 82% gross margin.
The company recorded net loss of $2,180 for the six months, but after $162,185 of cumulative preferred dividends, loss available to common stockholders was $164,365. Cash increased to $158,907, aided by $94,579 cash provided by operating activities. However, Vycor disclosed a working capital deficiency of $4,294,543, total liabilities of $5,064,398, and stockholders’ deficiency of $(4,251,224). Management stated that recurring losses, negative working capital and dependence on related-party financing raise substantial doubt about the company’s ability to continue as a going concern. A $300,000 EuroAmerican note plus $592,833 accrued interest is due December 31, 2026, and its further extension is uncertain.
Vycor Medical, Inc. reported Q1 2026 revenue of $458,540, up modestly from 2025, and net income of $20,108. After $162,185 of preferred dividends, common shareholders recorded a net loss of $142,077.
Cash improved to $173,634, but the company has a working capital deficit of $4,297,001 and total liabilities of $5,083,027. Management discloses “substantial doubt” about Vycor’s ability to continue as a going concern, citing heavy related-party obligations and a $300,000 EuroAmerican note at 16% interest maturing on June 30, 2026.
Vycor Medical (VYCO) filed its quarterly report, highlighting higher sales alongside continued financial pressure. Q3 revenue was $513,792, up 31% year over year, led by Vycor Medical products, with gross profit of $451,932. The company produced operating income of $32,085 versus a prior-year loss, and reported net income of $4,936 before preferred dividends.
After $162,185 in cumulative preferred dividends for the quarter, net loss available to common stockholders was $(157,249). Cash was $64,230 and the working capital deficit was $(4,152,481). Total liabilities stood at $4,965,388 and stockholders’ deficiency at $(4,024,193). Management disclosed substantial doubt about the company’s ability to continue as a going concern.
The filing notes a $300,000 EuroAmerican note (accrued interest $556,932) extended to March 31, 2026 and an SBA EIDL balance of $136,745. There were 33,372,796 common shares outstanding as of November 14, 2025.